Tempus AI, Inc. (NASDAQ:TEM) Director Nadja West Sells 809 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) Director Nadja West sold 809 shares of the firm’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $51.11, for a total value of $41,347.99. Following the completion of the transaction, the director now owns 37,705 shares of the company’s stock, valued at approximately $1,927,102.55. This represents a 2.10 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Tempus AI Trading Down 7.9 %

NASDAQ TEM opened at $48.86 on Friday. The business has a 50 day simple moving average of $53.75 and a two-hundred day simple moving average of $52.57. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. Tempus AI, Inc. has a 1-year low of $22.89 and a 1-year high of $91.45.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Bank of America lifted their price target on Tempus AI from $54.00 to $60.00 and gave the company a “neutral” rating in a research report on Monday. Loop Capital dropped their target price on Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research report on Tuesday, January 14th. Wolfe Research downgraded Tempus AI from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 26th. Morgan Stanley boosted their price objective on Tempus AI from $50.00 to $60.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, JPMorgan Chase & Co. downgraded Tempus AI from an “overweight” rating to a “neutral” rating and upped their target price for the company from $50.00 to $55.00 in a report on Tuesday, February 25th. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $61.18.

Hedge Funds Weigh In On Tempus AI

Institutional investors have recently added to or reduced their stakes in the company. Operose Advisors LLC purchased a new position in Tempus AI during the 4th quarter valued at approximately $25,000. First Horizon Advisors Inc. purchased a new position in shares of Tempus AI in the 3rd quarter worth approximately $30,000. Farther Finance Advisors LLC purchased a new position in shares of Tempus AI in the 4th quarter worth approximately $34,000. Prestige Wealth Management Group LLC boosted its holdings in shares of Tempus AI by 910.4% in the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock worth $36,000 after purchasing an additional 965 shares during the period. Finally, NewEdge Advisors LLC purchased a new position in shares of Tempus AI in the 4th quarter worth approximately $49,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.